Viking Therapeutics, Inc.

World-Wide Activities


2

analized transaction

205 Eur. ML

aggregated deals value

Last 12 months dossier

2

analized transaction

205 Eur. ML

aggregated deals value

Full dossier

Legal Advisors

Search

A world map will load here!







News

  • 10/6/2018
  • EN

    Viking Therapeutics's $175.8 Million Public Offering of Stock

    Paul Hastings represented Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, in its $175.8 million underwritten public offering of common stock.
  • 2/12/2018
  • EN

    Viking Therapeutics, Inc.'s $63.25 Million Initial Public Offering

    Paul Hastings LLP represented Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, in its $63.25 million underwritten public offering of common stock.

Practice Area

FusionCharts XT will load here!

Results are based upon public information and may undervalue a law firm's and/or a lawyer's professional experience and client portfolio.